Johnson & Johnson Profit Margin 2012-2026 | JNJ

Current and historical gross margin, operating margin and net profit margin for Johnson & Johnson (JNJ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Johnson & Johnson net profit margin as of June 30, 2026 is 21.48%.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $663.276B $94.193B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $1081.958B 36.50
AbbVie (ABBV) United States $453.112B 23.59
Merck (MRK) United States $370.890B 46.83
Roche Holding AG (RHHBY) Switzerland $350.157B 0.00
Novartis AG (NVS) Switzerland $305.285B 18.43
Novo Nordisk (NVO) Denmark $208.069B 11.59
Pfizer (PFE) United States $162.156B 9.33
Sanofi (SNY) France $107.257B 9.03
Bayer (BAYRY) Germany $55.767B 9.92
Innoviva (INVA) United States $1.541B 5.27